EMC3 and lung disorder: Amelioration of both the alveolar simplification and mitochondrial dysfunction associated with SFTPCI73T by deletion or inhibition of EMC3 or VCP identifies these pathways for development of pharmacological therapy of SFTPCI73T-associated lung disease.